Article about the study I'd worked on for the last few years.
"The other study, led by the International Clinical Research Center at the University of Washington, Seattle, found that daily PrEP reduced HIV transmission among approximately 4800 heterosexual serodiscordant couples in Kenya and Uganda. Uninfected partners received the combination of tenofovir and emtricitabine, tenofovir (Viread, Gilead Sciences) alone, or a placebo. The infected partners did not meet immunological criteria set by Kenya and Uganda to qualify for antiretroviral therapy.
Those patients who received tenofovir alone had an average of 62% fewer HIV infections than the placebo group, according to preliminary study results. The risk reduction was even higher for the group receiving the combination of tenofovir and emtricitabine, at 73%. Because of the efficacy of the PrEP approach, an independent group of advisors monitoring the study recommended discontinuing the placebo group of the study and releasing the preliminary data."